I just wanted to post this here, as it seems interest in raising NAD is high among pharma companies. While nicotinamide riboside is the most popular precursor used in the Western world, nicotinamide mononucleotide (NMN) is another one that has been used clinically. This clinical trial below, already underway in Japan, will test the effects of 6-month NMN administration on a long list of biomarkers related to mitochondrial function, steroid synthesis, and anti-aging. Interestingly, the doses used are quite in line with what Peat recommends for niacinamide. The higher dose in the trial will be 200mg NMN daily.
So, it would be interesting to see what results this produces as it would suggest the same can be achieved with niacinamide supplementation.
To Accelerate Research on Anti-aging and Age-related Disease, In Light of the Near Future of a Super-aging Society, Notice of Transfer of Hakushindo Pharmaceutical Co., Ltd. Shares
"...Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo, CEO Daizo Shimamura) provided research funding to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences to carry out the world's first clinical study regarding long-term (24 weeks) oral intake of NMN (β-nicotinamide mononucleotide). The name of the trial is: Evaluation of the effects of long-term ingestion of nicotinamide mononucleotide (NMN). The purpose of the trial is to confirm an increase in rejuvenating hormones, activation of mitochondria, and to confirm the emergence of sirtuin genes 1 and 2."
|NIPH Clinical Trials Search
"...Intervention(s) (1) Subjects receive 100 mg/day of NMN for 24 weeks. (2) Subjects receive 200 mg/day of NMN for 24 weeks."
"...i) Serum or plasma concentration of the following parameters at baseline, weeks 4, 8, 12, 18, and 24. *Thyroid-stimulating hormone (TSH) *Free triiodothyronine (Free T3) *Free thyroxine (Free T4) *Growth hormone (GH) *Prolactin *Parathyroid hormone (PTH) *Dehydroepiandrosterone sulfate (DHEA-S) *Estradiol (E2) *Testosterone *Calcitonin *Adrenocorticotropic hormone (ACTH) *Arginine vasopressin (AVP) *Cortisol *Aldosterone *Ghrelin *Inhibin *Melatonin ii) Mitochondria activity in leucocyte at baseline and week 24. iii) Sirt1 and Sirt2 gene expressions in leucocyte at baseline and week 24."
So, it would be interesting to see what results this produces as it would suggest the same can be achieved with niacinamide supplementation.
To Accelerate Research on Anti-aging and Age-related Disease, In Light of the Near Future of a Super-aging Society, Notice of Transfer of Hakushindo Pharmaceutical Co., Ltd. Shares
"...Hakushindo Pharmaceutical Co., Ltd. (head office: Shinjuku-ku, Tokyo, CEO Daizo Shimamura) provided research funding to the Project Research Center For Clinical Trials and Preventative Medicine at the Hiroshima University Graduate School of Biomedical & Health Sciences to carry out the world's first clinical study regarding long-term (24 weeks) oral intake of NMN (β-nicotinamide mononucleotide). The name of the trial is: Evaluation of the effects of long-term ingestion of nicotinamide mononucleotide (NMN). The purpose of the trial is to confirm an increase in rejuvenating hormones, activation of mitochondria, and to confirm the emergence of sirtuin genes 1 and 2."
|NIPH Clinical Trials Search
"...Intervention(s) (1) Subjects receive 100 mg/day of NMN for 24 weeks. (2) Subjects receive 200 mg/day of NMN for 24 weeks."
"...i) Serum or plasma concentration of the following parameters at baseline, weeks 4, 8, 12, 18, and 24. *Thyroid-stimulating hormone (TSH) *Free triiodothyronine (Free T3) *Free thyroxine (Free T4) *Growth hormone (GH) *Prolactin *Parathyroid hormone (PTH) *Dehydroepiandrosterone sulfate (DHEA-S) *Estradiol (E2) *Testosterone *Calcitonin *Adrenocorticotropic hormone (ACTH) *Arginine vasopressin (AVP) *Cortisol *Aldosterone *Ghrelin *Inhibin *Melatonin ii) Mitochondria activity in leucocyte at baseline and week 24. iii) Sirt1 and Sirt2 gene expressions in leucocyte at baseline and week 24."